The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
Open accessAbstract
Purpose: To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods: For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations: For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Marx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,648
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Osteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2465 · Cited by 593
Brown, J. E., Cook, R. J., Major, P., Lipton, A., Saad, F., Smith, M., Lee, K.-A., Zheng, M., Hei, Y.-J., & Coleman, R. E. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji002 · Cited by 559
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Generalisability in economic evaluation studies in healthcare: a review and case studies
Sculpher, M., Pang, F., Manca, A., Drummond, M., Golder, S., Urdahl, H., Davies, L., & Eastwood, A. (2004) · Health Technology Assessment · doi:10.3310/hta8490 · Cited by 441
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
Markowitz, G. S., Fine, P. L., Stack, J. I., Kunis, C. L., Radhakrishnan, J., Palecki, W., Park, J., Nasr, S. H., Hoh, S., Siegel, D. S., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00071.x · Cited by 384
Renal Failure with the Use of Zoledronic Acid
(2003) · New England Journal of Medicine · doi:10.1056/nejm200310233491721 · Cited by 367
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Dimopoulos, M. A., Kastritis, E., Anagnostopoulos, A., Melakopoulos, I., Gika, D., Moulopoulos, L. A., Bamia, C., Terpos, E., Tsionos, K., & Bamias, A. (2006) · PubMed · Cited by 340
Zervas, K., Verrou, E., Teleioudis, Z., Vahtsevanos, K., Banti, A., Mihou, D., Krikelis, D., & Terpos, E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06230.x · Cited by 297
Bisphosphonates for the relief of pain secondary to bone metastases
Wong, R. K., & Wiffen, P. J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002068 · Cited by 285
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
Bagan, J. V., Murillo, J., Jimenez, Y., Poveda, R., Milian, M. A., Sanchis, J. M., Silvestre, F. J., & Scully, C. (2005) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2004.00269.x · Cited by 266
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Greipp, P. R., Gollbach, K. L., Hayman, S. R., Kumar, S., Lust, J. A., Rajkumar, S. V., Russell, S. J., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1047 · Cited by 228
Self-citationBisphosphonates in multiple myeloma
Djulbegović, B., Wheatley, K., Ross, H. F., Clark, O. A. C., Bos, G. M. J., Goldschmidt, H., Cremer, F. W., Alsina, M., & Glasmacher, A. G. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188 · Cited by 141
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
Hoff, A. O., Toth, B. B., Altundağ, K., Guarneri, V., Adamus, A., Nooka, A. K., Sayegh, G., Johnson, M. M., Gagel, R. F., & Hortobágyi, G. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8528 · Cited by 133
Bisphosphonates and Ocular Inflammation
Fraunfelder, F. W., & Fraunfelder, F. T. (2003) · New England Journal of Medicine · doi:10.1056/nejm200303203481225 · Cited by 125
Podocyte injury associated glomerulopathies induced by pamidronate
Barri, Y. M., Munshi, N. C., Sukumalchantra, S., Abul‐Ezz, S. R., Bonsib, S. M., Wallach, J., & Walker, P. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00426.x · Cited by 104
Coukell, A. J., & Markham, A. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00007 · Cited by 82
Zoledronic Acid and Renal Toxicity: Data from French Adverse Effect Reporting Database
Munier, A., Gras, V., Andréjak, M., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e589 · Cited by 79
Bujanda, D. A., Sarmiento, U. B., Suárez, M. Á. C., & Morales, J. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl408 · Cited by 69
Tosi, P., Zamagni, E., Cangini, D., Tacchetti, P., Raimondo, F. D., Catalano, L., D’Arco, A. M., Ronconi, S., Cellini, C., Offidani, M., et al. (2006) · Blood · doi:10.1182/blood-2006-07-033571 · Cited by 62
Carella, A. M., Musto, P., Falcone, A. P., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L. M. A., Scalzulli, P. R., Dell’Olio, M., Sala, A. L., et al. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000099715 · Cited by 58
Sauter, M., Jülg, B. D., Porubský, Š., Cohen, C., Fischereder, M., Sitter, T., Schlöndorff, D., & Gröne, H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.02.189 · Cited by 42
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationTomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Self-citationMorgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575
Metadata
- Authors
- Kyle, R. A., Yee, G. C., Somerfield, M. R., Flynn, P. J., Halabi, S., Jagannath, S., Orlowski, R. Z., Roodman, D. G., Twilde, P., & Anderson, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-10
- Volume
- 25
- Issue
- 17
- Pages
- 2464-2472
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165326697
- Cited by
- 409
- References
- 36
- FWCI
- 24.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.